iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

(NASDAQ:IBIO), Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation New non-human primate data projects a human half-life of up to 100 days, potentially enabling treatment with only twice-yearly dosing Extended half-life data and differentiated mechanism of action reinforce […]

HPQ Receives First Industrial Shipments of HPQ ENDURA+ Batteries

(TSX-V:HPQ),(OTC US:HPQFF),(Other OTC:HPQFF),(Boerse Frankfurt – Freiverkehr:O08.F), MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, announces that it has received its first industrial shipments of HPQ ENDURA+ lithium-ion battery cells from the

Sprott Announces Date for 2025 Third Quarter Results Webcast

(TSX:SII),(NYSE:SII), TORONTO, Oct. 30, 2025 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE:SII) (TSX:SII) (“Sprott”) announced today that it plans to release its 2025 third quarter results at 7:00 a.m. on November 5, 2025. Sprott will host an earnings webcast that morning at 10:00 a.m. to discuss the results. Sprott CEO, Whitney George, together with Sprott CFO,

Abercrombie & Fitch and Luxury Retailer Kemo Sabe Debut Western-Inspired Collaboration

(NYSE:ANF), NEW ALBANY, Ohio, Oct. 30, 2025 (GLOBE NEWSWIRE) — Abercrombie & Fitch (Abercrombie), a division of Abercrombie & Fitch Co. (NYSE: ANF), today announced a global collaboration with Kemo Sabe, the Aspen-based luxury western retailer known for its premium boots, hats and western apparel. The women's-only collection includes genuine leather apparel and accessories, denim

Tilray Brands Sets Sights on Asia: Bringing Award-Winning Craft Beers to Japan’s Premier American Craft Beer Experience Festival

(NASDAQ:TLRY),(TSX:TLRY), NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is bringing its celebrated craft beer brands to the heart of Asia. Tilray will debut select craft brands at the

Bitfarms Schedules Third Quarter 2025 Conference Call on November 13, 2025

(TSX:BITF),(NasdaqGM:BITF), TORONTO and NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ/TSX: BITF) (“Bitfarms” or the “Company”), a North American energy and digital infrastructure company, will report its third quarter 2025 financial results on Thursday, November 13th before the market opens. Management will host a conference call on the same day at 8:00

Nurix Therapeutics to Participate in Upcoming Investor Conferences

(NasdaqGM:NRIX), SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences

LKQ Corporation Announces Results for Third Quarter 2025

(NASDAQ:LKQ), Simplified Portfolio with Successful Closing on Sale of Self Service Segment Returned $118 Million of Capital to Shareholders; $40 Million of Share Repurchases and $78 Million in Cash Dividends Raised Midpoint and Narrowed Range for Full Year 2025 EPS Outlook Following Sale of Self Service ANTIOCH, Tenn., Oct. 30, 2025 (GLOBE NEWSWIRE) — LKQ

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 GlobeNewswire October 30, 2025 LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it

Scroll to Top